Alpha Tau Medical Ltd. to Post Q2 2025 Earnings of ($0.13) Per Share, HC Wainwright Forecasts (NASDAQ:DRTS)

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Alpha Tau Medical in a research report issued on Wednesday, May 22nd. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.51) per share.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02.

Alpha Tau Medical Trading Down 4.5 %

DRTS stock opened at $2.53 on Thursday. The business has a fifty day moving average price of $2.71 and a 200 day moving average price of $2.93. Alpha Tau Medical has a fifty-two week low of $2.15 and a fifty-two week high of $4.80. The stock has a market capitalization of $176.27 million, a price-to-earnings ratio of -6.17 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.60 and a quick ratio of 12.07.

Institutional Investors Weigh In On Alpha Tau Medical

Hedge funds and other institutional investors have recently bought and sold shares of the business. USAdvisors Wealth Management LLC acquired a new stake in Alpha Tau Medical during the 1st quarter valued at $30,000. Telemus Capital LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at $89,000. Satovsky Asset Management LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at $176,000. Private Advisor Group LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at $176,000. Finally, Levin Capital Strategies L.P. boosted its position in Alpha Tau Medical by 288.4% in the 4th quarter. Levin Capital Strategies L.P. now owns 330,123 shares of the company’s stock valued at $994,000 after buying an additional 245,123 shares during the last quarter. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.